Oncolytics Biotech

Yahoo Finance • last year

Oncolytics Biotech's® Pelareorep Selected for Inclusion in Precision PromiseSM Pivotal Phase 3 Platform Trial

Adaptive clinical trial designed to accelerate registration pathways for pancreatic cancer therapies and expected to reduce cost of a Phase 3 study for pelareorep by ~50% compared to a traditional trial If successful, new clinical study e... Full story

Yahoo Finance • 2 years ago

Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights

Conference call and webcast to take place on Thursday, August 11, 2022, at 8:30 a.m. ET SAN DIEGO, CA and CALGARY, AB, July 27, 2022 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conferenc... Full story

Yahoo Finance • 3 years ago

Oncolytics Biotech® Reports First Quarter 2022 Financial Results and Recent Operational Highlights

Anticipated Q4 2022 data readout from randomized phase 2 study in breast cancer is on track and expected to inform the design of a registrational trial Clinical biomarker data demonstrates pelareorep's induced improvement in the prognosis... Full story

Yahoo Finance • 3 years ago

Oncolytics Biotech® Provides Positive Safety Update on the Third-Line Metastatic Colorectal Cancer Cohort of its Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial

Independent review identified, no safety concerns in trial's final safety run-in Cohort supported by prior clinical data showing a pelareorep-based combination driving a 90% clinical benefit rate in KRAS-mutated colorectal cancer patients... Full story